Form 4: Cogent Biosciences CCO Boosts Stake, Gains Options

Cogent Biosciences' Chief Commercial Officer, Cole Pinnow, increased beneficial ownership through RSU vesting and new option grants, while also selling shares for tax obligations.

Summary

• Cole Pinnow, Chief Commercial Officer of Cogent Biosciences, Inc. (COGT), reported changes in beneficial ownership.
• Acquired 50,000 Restricted Stock Units (RSUs) under the Issuer's 2018 Stock Option and Incentive Plan, which will vest 1/4th annually over four years.
• Acquired 214,000 shares of common stock in connection with the vesting of a performance-based RSU award granted in February 2023 (the "2023 PSUs").
• Disposed of 94,800 shares of common stock at a price of $39.45 per share to satisfy required tax withholdings related to the vesting of the 2023 PSUs.
• Acquired 65,000 stock options with an exercise price of $39.45, which will vest in equal monthly installments over a four-year period and expire on December 17, 2035.
• Beneficial ownership of common stock following these reported transactions is 216,650 shares, which includes previously reported shares underlying RSUs subject to vesting conditions.
• An aggregate of 1,602 shares of common stock were acquired by the reporting person under the Issuer's 2018 Employee Stock Purchase Plan on June 30, 2025.

Sentiment

Score: 7

Explanation: The overall sentiment is moderately positive. While there was a sale of shares for tax purposes, this is offset by the vesting of a significant number of performance-based RSUs and the grant of new RSUs and stock options, indicating continued executive alignment and confidence in future performance.

Positives

• Chief Commercial Officer Cole Pinnow received a significant grant of 50,000 Restricted Stock Units, aligning his interests with long-term shareholder value.
• Pinnow also received 65,000 new stock options, further incentivizing performance tied to the company's stock price.
• The vesting of 214,000 performance-based RSUs indicates the achievement of prior performance targets by the company and its executive.
• The net effect of the transactions (excluding tax-related sales) shows an increase in potential beneficial ownership through new RSU and option grants, signaling continued executive confidence.

Negatives

• Cole Pinnow disposed of 94,800 shares of common stock to satisfy tax withholding obligations, representing a sale of company stock.

Future Outlook

The reporting person's equity awards, including 50,000 RSUs and 65,000 stock options, are subject to multi-year vesting schedules, indicating a long-term incentive structure tied to continued service and future company performance. The RSUs will vest 1/4th annually over four years, and the stock options will vest in equal monthly installments over four years.

Industry Context

Insider transactions, such as RSU vesting, option grants, and subsequent tax-related sales, are standard practices in executive compensation across the biotechnology and pharmaceutical industries. These mechanisms are designed to align executive interests with long-term shareholder value and incentivize performance. The grant of new equity awards to a Chief Commercial Officer suggests a continued focus on commercial strategy and growth for Cogent Biosciences.

Stakeholder Impact

• Shareholders: The grant of new equity awards and the vesting of performance-based RSUs for the Chief Commercial Officer may signal management's continued commitment and alignment with shareholder interests, potentially boosting investor confidence.
• Employees: The equity compensation structure, including RSUs and stock options, is a key component of executive incentives, which can influence overall company culture and performance expectations.

Next Steps

• The 50,000 newly granted RSUs will vest in 1/4th increments on each anniversary of the grant date over the next four years.
• The 65,000 newly granted stock options will vest in equal monthly installments over the next four years.

Key Dates

Recommendation

The filing details routine executive compensation events, including the vesting of performance-based RSUs and the grant of new equity awards (RSUs and stock options), alongside a tax-related sale. While the new grants and vesting demonstrate continued executive alignment and achievement of past performance metrics, the tax-related sale is a common occurrence and not a discretionary sell-off. This information alone does not provide a strong catalyst for a 'buy' or 'sell' recommendation but rather reinforces a 'hold' position, awaiting broader financial performance or strategic updates.

Keywords

Cogent Biosciences, COGT, Form 4, Insider Trading, Restricted Stock Units, RSU, Stock Options, Beneficial Ownership, Chief Commercial Officer, Executive Compensation, Equity Grant